Alternative Data for Haemonetics Corporation
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 100 | Sign up | Sign up | Sign up |
| Sentiment | 85 | Sign up | Sign up | Sign up |
| Webpage traffic | 49,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 29 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,724 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 637 | Sign up | Sign up | Sign up |
| X Followers | 959 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 42 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,510 | Sign up | Sign up | Sign up |
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
| Price | $56.29 |
| Target Price | Sign up |
| Volume | 1,122,318 |
| Market Cap | $2.62B |
| Year Range | $47.67 - $87.16 |
| Dividend Yield | 0% |
| PE Ratio | 15.51 |
| Analyst Rating | 78% buy |
| Industry | Medical Devices |
In the news
 |
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations WebsiteMay 7 - PRNewswire |
Mizuho Adjusts Haemonetics Corporation (HAE) Estimates in Sector-Wide ReviewApril 17 - Yahoo Entertainment |
|
 |
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81February 17 - Yahoo |
|
Assessing Haemonetics (HAE) Valuation After Recent Share Price WeaknessFebruary 17 - Yahoo |
|
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings GrowthFebruary 15 - Yahoo |
|
Haemonetics (HAE) International Revenue Performance ExploredFebruary 9 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 346M | 148M | 198M | -20M | 51M | 1.290 |
| Q4 '25 | 339M | 148M | 191M | 45M | 97M | 0.950 |
| Q3 '25 | 327M | 144M | 183M | 39M | 96M | 1.270 |
| Q2 '25 | 321M | 130M | 192M | 34M | 94M | 1.100 |
| Q1 '25 | 331M | 138M | 193M | 58M | 100M | 1.240 |
Insider Transactions View All
| KROLL MARK W filed to buy 24,757 shares at $70.6. November 12 '25 |
| Strong Stewart W filed to sell 18,196 shares at $91.2. July 29 '24 |
| Lingamneni Anila filed to sell 21,331 shares at $90. July 15 '24 |
| Lingamneni Anila filed to sell 21,410 shares at $90. July 15 '24 |
| Strong Stewart W filed to sell 18,196 shares at $87.5. May 29 '24 |
Similar companies
Read more about Haemonetics Corporation (HAE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Haemonetics Corporation
The Market Cap of Haemonetics Corporation is $2.62B.
As of today, Haemonetics Corporation's PE (Price to Earnings) ratio is 15.51.
Currently, the price of one share of Haemonetics Corporation stock is $56.29.
The HAE stock price chart above provides a comprehensive visual representation of Haemonetics Corporation's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Haemonetics Corporation shares. Our platform offers an up-to-date HAE stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Haemonetics Corporation (HAE) does not offer dividends to its shareholders. Investors interested in Haemonetics Corporation should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Haemonetics Corporation are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
